GOLFIERI FERNANDADACOSTA, ZANON MAURÍCIO, PERCIO PEDROPAULOVERONA. ATYPICAL FEMORAL FRACTURES DUE TO THE USE OF BISPHOSPHONATES: EPIDEMIOLOGIC STUDY IN A TERTIARY HOSPITAL.
ACTA ORTOPEDICA BRASILEIRA 2022;
30:e238821. [PMID:
35719180 PMCID:
PMC9177062 DOI:
10.1590/1413-785220223002238821]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 11/19/2021] [Indexed: 11/22/2022]
Abstract
Objective:
Show the relationship between atypical femoral fractures and prolonged use of
bisphosphonates and analyze the limit of its beneficial use.
Methods:
Retrospective cohort study (level of evidence 2B). From Atypical fracture
cases, patients who used bisphosphonates were selected and the time period
of their use was analyzed. Additionally, the variables sex, age, and the
side most affected were studied.
Results:
Nine atypical femur fractures were found, all associated with the use of
bisphosphonates. The average period of use of this medication was nine years
(minimum of three years; maximum of 14 years). The patients’ mean age was of
78 years (69-88 years) and all were women, with the right member being the
most affected.
Conclusion:
The use of bisphosphonates to prevent osteoporotic fractures has been
increasingly frequent and, when used for a prolonged period, it has been
related to atypical fractures. Further scientific studies on doses, maximum
periods of treatment, and risk-benefit in the indication of these
medications are needed to assist in therapeutic management for each case. Level of Evidence II, Retrospective Study.
Collapse